Cargando…

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibition

Purpose: Lacking effective targeted therapies, triple-negative breast cancer (TNBCs) is highly aggressive and metastatic disease, and remains clinically challenging breast cancer subtype to treat. Despite the survival dependency on the proteasome pathway genes, FDA-approved proteasome inhibitors ind...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raninga, Prahlad V., Lee, Andy, Sinha, Debottam, Dong, Lan-feng, Datta, Keshava K., Lu, Xue, Kalita-de Croft, Priyakshi, Dutt, Mriga, Hill, Michelle, Pouliot, Normand, Gowda, Harsha, Kalimutho, Murugan, Neuzil, Jiri, Khanna, Kum Kum
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196287/ https://www.ncbi.nlm.nih.gov/pubmed/32373211 http://dx.doi.org/10.7150/thno.42705

Ejemplares similares

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8(+) T-cells infiltration in triple-negative breast cancer
por: Kalimutho, Murugan, et al.
Publicado: (2019)

Cep55 overexpression promotes genomic instability and tumorigenesis in mice
por: Sinha, Debottam, et al.
Publicado: (2020)

GSK3-β Stimulates Claspin Degradation via β-TrCP Ubiquitin Ligase and Alters Cancer Cell Survival
por: Cabrera, Elisa, et al.
Publicado: (2019)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer
por: Kalimutho, Murugan, et al.
Publicado: (2018)

Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo
por: Manton, Christa A., et al.
Publicado: (2016)

The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells
por: Anderson, Alison M., et al.
Publicado: (2017)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

Enhanced dependency of KRAS‐mutant colorectal cancer cells on RAD51‐dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae
por: Kalimutho, Murugan, et al.
Publicado: (2017)

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma
por: Sze, Jun Hui, et al.
Publicado: (2019)

Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
por: Potts, Barbara C., et al.
Publicado: (2010)

Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis
por: Rashidieh, Behnam, et al.
Publicado: (2021)

Targeting BRF2 in Cancer Using Repurposed Drugs
por: Rashidieh, Behnam, et al.
Publicado: (2021)

Marizomib: A novel therapeutic approach for the treatment of central nervous system myeloma
por: Bazou, Despina, et al.
Publicado: (2020)

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis
por: Hancock, Janelle L., et al.
Publicado: (2023)

Enhanced proteasomal activity is essential for long term survival and recurrence of innately radiation resistant residual glioblastoma cells
por: Rajendra, Jacinth, et al.
Publicado: (2018)

Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
por: Bota, Daniela A, et al.
Publicado: (2021)

Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonist
por: Boccellato, Chiara, et al.
Publicado: (2021)

Targeting mitochondrial energetics reverses panobinostat‐ and marizomib‐induced resistance in pediatric and adult high‐grade gliomas
por: Jane, Esther P., et al.
Publicado: (2023)

Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer
por: Adwal, Alaknanda, et al.
Publicado: (2020)

Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo
por: Zhang, Ziruizhuo, et al.
Publicado: (2022)

BRCA1 A-Complex fine tunes repair functions of BRCA1
por: Harris, Janelle L, et al.
Publicado: (2011)

RNA-binding protein NONO contributes to cancer cell growth and confers drug resistance as a theranostic target in TNBC
por: Kim, Seong-Jin, et al.
Publicado: (2020)

Peptidyl-prolyl isomerization for cytokinetic abscission: Fold and cut
por: van der Horst, Armando, et al.
Publicado: (2012)

Complexities of pharmacogenomic interactions in cancer
por: Khanna, Kum Kum, et al.
Publicado: (2020)

Emerging Biomarkers for Diagnosis, Prevention and Treatment of Brain Metastases—From Biology to Clinical Utility
por: Kalita-de Croft, Priyakshi, et al.
Publicado: (2022)

Signaling to the Epigenome: New Insights into the Roles of Nuclear Signaling Kinases in the Context of the Immune System and Cancer
por: Lim, Pek Siew, et al.
Publicado: (2017)

Ovarian-Cancer-Associated Extracellular Vesicles: Microenvironmental Regulation and Potential Clinical Applications
por: Croft, Priyakshi Kalita-de, et al.
Publicado: (2021)

Protocol for purification and identification of MHC class I immunopeptidome from cancer cell lines
por: Mohan, Sonali V., et al.
Publicado: (2021)

Temporal Quantitative Proteomics Reveals Proteomic and Phosphoproteomic Alterations Associated with Adaptive Response to Hypoxia in Melanoma Cells
por: Datta, Keshava K., et al.
Publicado: (2021)

Are estrogen receptor-positive breast cancers in BRCA1 mutation carriers sporadic?
por: Lakhani, Sunil R, et al.
Publicado: (2010)

Involvement of Exo1b in DNA damage-induced apoptosis
por: Bolderson, Emma, et al.
Publicado: (2009)

MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments
por: Miranda, Mariska, et al.
Publicado: (2015)

Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer
por: Zeng, Ruichao, et al.
Publicado: (2021)

Human single-stranded DNA binding protein 1 (hSSB1/NABP2) is required for the stability and repair of stalled replication forks
por: Bolderson, Emma, et al.
Publicado: (2014)

Cross Talk between Two Antioxidant Systems, Thioredoxin and DJ-1: Consequences for Cancer
por: Raninga, Prahlad V., et al.
Publicado: (2014)

ATM mediated phosphorylation of CHD4 contributes to genome maintenance
por: Urquhart, Aaron J, et al.
Publicado: (2011)

A Comprehensive Review on Current Advances in Peptide Drug Development and Design
por: Lee, Andy Chi-Lung, et al.
Publicado: (2019)

Proteomic Analysis of the Breast Cancer Brain Metastasis Microenvironment
por: Kalita-de Croft, Priyakshi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6u8vq61tpekve0phiss1vekfd7